Phase 3 Melanoma Trial, Recruiting NCT05727904 Sponsor: Iovance Biotherapeutics, Inc. Condition: Melanoma
Back to Melanoma

Phase 3 Melanoma Trial, Recruiting

NCT05727904
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with advanced melanoma (Stage IIIC, IIID, or IV) that cannot be fully removed by surgery or has spread to other parts of the body, confirmed by a lab test on a tissue sample.
  • Your doctor has assessed that you are generally well enough to carry out daily activities with little or no limitation, and your life expectancy is estimated to be more than 6 months.
  • You have at least one tumor (or group of tumors) that a surgeon can remove to be used to create a personalised cell therapy called lifileucel.
  • After the tumor removal, you still have at least one other measurable area of disease that doctors can track during the trial.
  • Your organs (such as kidneys, liver, and heart) are working well enough to safely take part.
  • If you or your partner could become pregnant, you must be willing to use a highly effective method of birth control during the trial.
  • If you are over 70 years old, you may still be considered after your doctor discusses your case with the trial medical team.

Who may not be able to join:

  • Your melanoma started in the eye (uveal or ocular melanoma).
  • You have brain metastases (cancer that has spread to the brain) that are causing symptoms and have not been treated.
  • You have already received more than one previous treatment course for your melanoma.
  • You have previously received any treatment specifically for metastatic (spread) disease.
  • If your tumor has a specific gene change called BRAF V600 mutation, and you have only received a type of immune therapy (called ICI) before surgery as a preventative treatment, you may not be eligible (confirm with trial site).
  • You have an active serious illness — such as an ongoing infection, seizure disorder, blood clotting disorder, or significant heart, lung, or immune system condition — that your doctor believes could make participation risky.
  • You have any condition that weakens your immune system, such as a severe immune deficiency (e.g., SCID) or AIDS.
  • You have had another type of cancer diagnosed within the last 3 years, unless it did not need treatment or was fully treated more than 1 year ago and your doctor does not think it is likely to return.
  • You have previously had a transplant of an organ or cells from another person.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Iovance Biotherapeutics Study Team, Iovance Biotherapeutics

Phone: 1-844-845-4682

Australian sites

Greenslopes Private Hospital, Greenslopes, Queensland
Peter MacCallum Cancer Centre, Melbourne, Victoria
Fiona Stanley Hospital, Murdoch, Western Australia
Flinders Medical Centre, Bedford Park,
Westmead Hospital, Westmead,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Iovance Biotherapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
30 March 2023
Est. completion
1 March 2028

Where this trial is recruiting

🇦🇺 Australia 🇧🇪 Belgium 🇨🇦 Canada 🇫🇮 Finland 🇫🇷 France 🇩🇪 Germany 🇮🇱 Israel 🇮🇹 Italy 🇳🇱 Netherlands 🇸🇬 Singapore 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland 🇬🇧 United Kingdom 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Objective Response Rate and Progression Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov